GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.
Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.
Conference Call Details
| Date: | Tuesday, November 10th |
| Time: | 8:30 am Eastern Time |
| Domestic: | 877-300-8521 |
| International: | 412-317-6026 |
| Conference ID: | 10149733 |
| Webcast: | http://public.viavid.com/index.php?id=142319 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
| Investor Contacts: | ||
| Will Brown | Ashley R. Robinson | |
| Chief Financial Officer | LifeSci Advisors, LLC | |
| Phone: 240-654-1450 | 617-430-7577 | |
| wbrown@altimmune.com | arr@lifesciadvisors.com | |
| Media Contacts: | ||
| Warren Rizzi | ||
| Sard Verbinnen & Co. | ||
| Phone: 212-687-8080 | ||
| altimmune-svc@sardverb.com |